

1 **Autoantigen profiling reveals a shared post-COVID signature in fully recovered and Long**  
2 **COVID patients**

3  
4 Aaron Bodansky,<sup>1</sup> Chung-Yu Wang,<sup>2</sup> Aditi Saxena,<sup>2</sup> Anthea Mitchell,<sup>2</sup> Saki Takahashi,<sup>3</sup> Khamal  
5 Anglin,<sup>4</sup> Beatrice Huang,<sup>3</sup> Rebecca Hoh,<sup>3</sup> Scott Lu,<sup>4</sup> Sarah A. Goldberg,<sup>4</sup> Justin Romero,<sup>3</sup> Brandon  
6 Tran,<sup>3</sup> Raushun Kirtikar,<sup>3</sup> Halle Grebe,<sup>3</sup> Matthew So,<sup>3</sup> Bryan Greenhouse,<sup>3</sup> Matthew S.  
7 Durstenfeld,<sup>5</sup> Priscilla Y. Hsue,<sup>5</sup> Joanna Hellmuth,<sup>6</sup> J. Daniel Kelly,<sup>4</sup> Jeffrey N. Martin,<sup>4</sup> Mark S.  
8 Anderson,<sup>7,8</sup> Steven G. Deeks,<sup>3</sup> Timothy J. Henrich,<sup>9</sup> Joseph L. DeRisi,<sup>2</sup> Michael J. Peluso<sup>3</sup>

9  
10 1 Division of Pediatric Critical Care Medicine, University of California, San Francisco, San  
11 Francisco, CA, USA

12 2 Chan Zuckerberg Biohub, San Francisco, CA, USA

13 3 Division of HIV, Infectious Diseases, and Global Medicine, University of California, San  
14 Francisco, San Francisco, CA, USA

15 4 Department of Epidemiology and Biostatistics, University of California, San Francisco, San  
16 Francisco, CA, USA

17 5 Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA

18 6 Department of Neurology University of California, San Francisco, San Francisco, CA, USA

19 7 Diabetes Center, University of California, San Francisco, San Francisco, CA, USA

20 8 Department of Medicine, University of California, San Francisco, San Francisco, CA, USA

21 9 Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA,  
22 USA

23  
24 Corresponding Author: Aaron Bodansky, MD

25 (PhIP-Seq Questions) Division of Pediatric Critical Care Medicine

26 University of California, San Francisco

27 San Francisco, CA, USA

28 Email: [aaron.bodansky@ucsf.edu](mailto:aaron.bodansky@ucsf.edu)

29

30 Alternate Corresponding Author: Michael Peluso, MD

31 (Cohort Questions) Division of HIV, Infectious Diseases, and Global Medicine

32 University of California, San Francisco

33 San Francisco, CA, USA

34 Email: [michael.peluso@ucsf.edu](mailto:michael.peluso@ucsf.edu)

35

36 **Keywords:** SARS-CoV-2, COVID-19, post-acute sequelae of SARS-CoV-2 infection (PASC),

37 Long COVID, autoreactivity, autoimmunity, autoantigen

38 **ABSTRACT**

39 Some individuals do not return to baseline health following SARS-CoV-2 infection, leading to a  
40 condition known as Long COVID. The underlying pathophysiology of Long COVID remains  
41 unknown. Given that autoantibodies have been found to play a role in severity of COVID infection  
42 and certain other post-COVID sequelae, their potential role in Long COVID is important to  
43 investigate. Here we apply a well-established, unbiased, proteome-wide autoantibody detection  
44 technology (PhIP-Seq) to a robustly phenotyped cohort of 121 individuals with Long COVID, 64  
45 individuals with prior COVID-19 who reported full recovery, and 57 pre-COVID controls. While a  
46 distinct autoreactive signature was detected which separates individuals with prior COVID  
47 infection from those never exposed to COVID, we did not detect patterns of autoreactivity that  
48 separate individuals with Long COVID relative to individuals fully recovered from SARS-CoV-2  
49 infection. These data suggest that there are robust alterations in autoreactive antibody profiles  
50 due to infection; however, no association of autoreactive antibodies and Long COVID was  
51 apparent by this assay.

52

## 53 **BACKGROUND**

54 Some individuals do not fully return to baseline health following SARS-CoV-2 infection and  
55 experience ongoing morbidity following the acute phase of COVID-19 (1, 2). There is now intense  
56 interest in determining the underlying mechanisms of Long COVID, one type of post-acute  
57 sequelae of SARS-CoV-2 infection (PASC) characterized by symptoms that newly developed or  
58 worsened following infection that cannot be clearly attributed to another cause (3). Immune  
59 dysregulation, including the generation of antibodies against self antigens, has been suggested as  
60 one potential driver of Long COVID that warrants further investigation (4, 5).

61  
62 Acute SARS-CoV-2 infection is associated with the generation of autoreactive antibodies,  
63 particularly among individuals with severe disease requiring hospitalization (6–8). For example,  
64 one study of 147 individuals hospitalized with COVID-19 found that autoantibodies associated with  
65 connective tissue diseases and anti-cytokine antibodies were identified in 50% of samples, and  
66 tracked with the humoral response to SARS-CoV-2 infection (7). Furthermore, multiple studies  
67 have described the contribution of likely pre-existing anti-interferon antibodies to vaccine  
68 breakthrough infections and severe manifestations of COVID-19, including death (9–12).

69  
70 Although much work has been done exploring the potential virologic and immunologic factors  
71 driving Long COVID, the evaluation of autoantibodies in this condition has been more limited.  
72 Measurement of anti-nuclear antibodies on standard clinical tests has yielded mixed findings, with  
73 some studies identifying a high prevalence of antinuclear antibodies (ANAs) among those with  
74 Long COVID (13–15) and other studies finding low prevalence consistent with ANA positivity in  
75 the general population (16–18). Although perturbations in interferon signaling pathways have been  
76 suggested as one potential mechanism of Long COVID (4, 15), anti-interferon antibodies have not  
77 been identified in most individuals outside of those who had severe acute infection (16). This is

78 consistent with other post-acute sequelae of COVID such as multisystem inflammatory syndrome  
79 in children (MIS-C), which also has no association with anti-interferon antibodies (19).

80

81 The identification of previously reported autoantibodies can be performed using targeted assays.  
82 However, identifying the full range of novel autoreactive antibodies, whether they are pathological  
83 or not, requires technologies capable of high-throughput, unbiased, proteome-wide screens. In  
84 this study, we screened a cohort of individuals with prior SARS-CoV-2 infection, many of whom  
85 met clinical criteria for Long COVID, to determine whether a consistent pattern of autoreactivity  
86 could be identified. This same technology has been previously utilized to discover novel  
87 autoantibodies in a wide range of disease contexts (20–23).

88

## 89 **RESULTS**

### 90 **Distinct set of autoreactive antibodies in individuals with prior SARS-CoV-2 infection**

91 We employed a previously published proteome-wide approach using a T7 phage-display assay  
92 with immunoprecipitation and next-generation sequencing (PhiP-Seq) (20–24). We tested sera  
93 from 185 otherwise healthy individuals with prior SARS-CoV-2 infection in parallel to sera from 57  
94 otherwise healthy individuals collected prior to the known existence of COVID-19 (pre-COVID).  
95 Using an unbiased analysis, we identified a distinct pattern of autoreactivity which effectively  
96 classifies individuals with prior SARS-CoV-2 infection from individuals not yet exposed to the virus  
97 with a logistic regression AUC of 0.90 (Figure 1A). The protein targets from which these enriched  
98 immunoprecipitated peptides were derived are widely varied and lack any apparent shared  
99 biological functions or cell type (Figure 1B). Among the identified targets, a single peptide derived  
100 from ARHGAP31 (Figure 2A) displayed the greatest amount of enrichment with 22% of individuals  
101 with prior SARS-CoV-2 infection yielding enrichment greater than 6 standard deviations of the

102 mean of the pre-COVID controls. No difference in enrichment was observed for those diagnosed  
103 with Long COVID with respect to Post-COVID (Figure 2B).

104

105 To investigate whether the ARHGAP31 peptide enrichment could be the result of cross-reactivity  
106 with antibodies directed against SARS-CoV-2 proteins, we performed a multiple sequence  
107 alignment of this 49-amino acid fragment against the full SARS-CoV-2 proteome. A region within  
108 the SARS-CoV2 Orf1a polyprotein was identified with considerable physico-chemical similarity to  
109 a portion of the autoreactive fragment in ARHGAP31(Jalview Version 2;Figure 2C), supporting the  
110 notion that the observed human peptidome peptide enrichments in post-COVID samples are being  
111 driven by anti-SARS-CoV-2 antibodies.

112

113 ARHGAP31 is most highly expressed in neuronal cells, Langerhans cells, and endothelial cells  
114 (Human Protein Atlas, [proteinallas.org](http://proteinallas.org)). We were unable to identify any clinical differences  
115 between individuals with and without ARHGAP31 autoreactivity, such as differences in frequency  
116 of neurologic symptoms.

117

### 118 **Post-COVID autoreactivities are not enriched in individuals with Long COVID**

119 To assess whether autoreactive antibodies present in individuals following SARS-CoV-2 infection  
120 are associated with Long COVID, we compared the distribution of the enriched post-COVID  
121 peptides amongst the 121 individuals with Long COVID and the 64 individuals with prior SARS-  
122 CoV-2 infection but without Long COVID (Convalescent COVID). The 20 most enriched proteins  
123 with at least 5-fold greater than background (defined as fold-change over mock-IP with protein  
124 A/G beads) were compared (Figure 3). Seventeen of the 20 enriched proteins were present in  
125 both Long COVID and Convalescent COVID, and none of these enrichments was observed in any  
126 of the pre-COVID controls. Overall, there was no significant differences in enrichment between

127 Long COVID and Convalescent COVID. Peptides derived from three proteins, TMED10, FUCA1,  
128 and POL2RK, were only observed in Long COVID, however these were infrequently observed.

129

130 Subgroup analyses were performed to determine whether any of these observed autoreactivities  
131 were enriched in particular symptom-defined phenotypes of Long COVID. These include  
132 cardiopulmonary (cough, shortness of breath, chest pain, palpitations, and fainting), central  
133 neurologic symptoms (problems with vision, headache, difficulty with concentration or memory,  
134 dizziness, and difficulty with balance), any neurologic symptom (problems with vision, headache,  
135 difficulty with concentration or memory, dizziness, difficulty with balance, trouble with smell or  
136 taste, phantosmia, or paresthesia), gastrointestinal (diarrhea, constipation, nausea, vomiting, loss  
137 of appetite, and abdominal pain), musculoskeletal (back pain, muscle pain, pain in the arms, legs,  
138 or joints), and upper respiratory (runny nose and sore throat).

139

140 The peptide enrichments from individuals with particular Long COVID phenotypes were compared  
141 to the enrichments from individuals with Convalescent COVID (no Long COVID symptoms) using  
142 a one-sided Kolmogorov-Smirnov test. None of the top 20 autoantibodies were enriched in severe  
143 Long COVID, and only 3 autoantibodies were statistically increased in any phenotype: TTF2 and  
144 KDM3B in those with cardiopulmonary symptoms and FUCA1 in those with upper respiratory  
145 symptoms (Figure 4A). However, using a strict cutoff of 6 standard deviations above the pre-  
146 COVID controls to determine positivity, none of these autoantibodies was phenotype specific. By  
147 looking at the distribution of these antibodies in Long COVID patients with given sub-phenotype  
148 relative to the remaining Long COVID patients and all convalescent COVID patients, it was  
149 apparent that the statistical significance in a particular phenotype was driven by either a single  
150 individual with extremely high autoantibody signal in the case of KDM3B and TTF2, or higher  
151 group signal but not meeting the positive threshold cutoff in the case of FUCA1 (Figure 4B).

## 152 **Absence of Long COVID specific autoreactivities**

153 In addition to analyzing the distribution of post-COVID autoreactive peptide enrichments, we also  
154 performed additional analyses to detect those enrichments which might be present only in Long  
155 COVID or particular subcategories of Long COVID. To feature-weight enriched peptides, we  
156 applied logistic regressions to the degree of enrichment for each individual with Long COVID and  
157 each individual Long COVID symptom phenotype versus enrichment from convalescent COVID  
158 patients who did not have the particular symptoms. We included all previously discussed symptom  
159 phenotypes, as well as individuals with difficulty concentrating, worsened quality of life, new  
160 depression, and generalized anxiety disorder. We were unable to identify a set of enriched  
161 proteins specific to any of these groups of patients which could effectively distinguish the cohort  
162 from controls, as the best receiver operating characteristic (ROC) area under the curve (AUC) was  
163 0.67, and the mean AUC was 0.44 (Supplement 1).

164

## 165 **DISCUSSION**

166 Autoimmunity has been proposed as one potential mechanism driving Long COVID. We applied  
167 an unbiased, proteome-wide, validated approach to assess associations between antibody  
168 autoreactivity and clinical phenotype. A clear and robust difference in autoreactivity was detected  
169 between those infected with SARS-CoV-2 and pre-COVID controls. This difference was  
170 constituted by peptides from diverse and varied proteins, most of which are intracellular,  
171 suggesting that the origin of the differential enrichment is due to cross-reactivity with SARS-CoV-2  
172 directed antibodies in those that were exposed. A sequence comparison between a peptide from  
173 the most enriched protein, ARHGAP31, and Orf1a of SARS-CoV-2 supports this notion, but  
174 orthogonal validation through fine-scale epitope mapping and antibody cloning would be required  
175 to demonstrate this conclusively. While the clinical significance of incidental autoreactivity due to  
176 the humoral immune response to SARS-CoV-2 remains largely unknown, prior studies have



177 identified cross reactive autoantibodies in severe sequelae of SARS-CoV-2 infection, including  
178 those that develop severe neurological symptoms (Song et al., 2021). Understanding the clinical  
179 consequences of SARS-CoV-2 driven autoreactivity deserves further attention, perhaps through  
180 long-term longitudinal studies.

181

182 We found no association to support the hypothesis that autoreactivity, as detected in this assay,  
183 contributes to Long COVID. Despite numerous successes, PhIP-seq possesses a number of  
184 limitations. Because the T7 phage displayed peptides are only 49 amino acids, the assay  
185 inherently detects mostly linear epitopes. Therefore, complex conformational, post translationally  
186 modified, or multimeric protein configurations are not predicted to be detectable by this assay, and  
187 thus these results do not completely rule out autoimmune interactions in Long COVID that are  
188 beyond the scope of PhIP-seq.

189

190 In addition, our classification of Long COVID and its symptom phenotypes was based exclusively  
191 on participant self-report of symptoms. It is possible that future analyses in more homogenous  
192 cohorts, particularly those with objectively measured physiologic perturbations now associated  
193 with certain Long COVID phenotypes (e.g., postural orthostasis/tachycardia, neurocognitive  
194 function deficits, abnormalities on cardiopulmonary exercise testing) may yet reveal a role of  
195 autoantibodies in at least a subset of individuals experiencing Long COVID.

196

197 Long COVID remains a complex clinical entity. Its causes are likely multifactorial, and there is  
198 growing consensus that different phenotypes are driven by different pathophysiologic mechanisms  
199 (2, 3). Additional work characterizing SARS-CoV-2 specific and autoreactive immune responses in  
200 large, well-characterized cohorts over time, during both the acute and post-acute phases of the  
201 illness, will be necessary to delineate the biology of Long COVID and other post-acute sequelae of

202 SARS-CoV-2 infection, and to lead to the development of potential interventions to treat the  
203 millions of individuals currently affected by this condition.

204

## 205 **METHODS**

### 206 **Study participants and measurements**

207 Participants were volunteers in the UCSF Long-term Impact of Infection with Novel Coronavirus  
208 (LIINC) study (NCT04362150). The details of study design and measurement have been reported  
209 previously (25). For the current analysis, we included 186 individuals with a history of nucleic acid-  
210 confirmed SARS-CoV-2 infection who had a plasma sample collected between 60 and 240 days  
211 following initial symptom onset or, if asymptomatic, first positive SARS-CoV-2 test. Long COVID  
212 was defined using study instruments, which have been described in detail elsewhere (25). Briefly,  
213 each participant was queried regarding the presence, severity, and duration of 32 physical and  
214 mental health symptoms and quality of life. Details of their medical history and COVID-19 infection  
215 and vaccination and treatment history were also recorded. Symptoms that pre-dated SARS-CoV-2  
216 infection and that were not changed following infection, as well as those obviously attributed to  
217 another cause (e.g. ankle fracture), were not considered to represent Long COVID. All samples  
218 included were collected prior to the subject ever receiving a SARS-CoV-2 vaccine.

219

220 Because of challenges in objectively defining Long COVID and to thoroughly explore the data in  
221 an unbiased manner, we utilized a number of predefined case definitions in our analysis. We  
222 constructed case definitions based on symptom presentation and quality-of-life (QOL) responses.  
223 Symptoms case definitions include: the presence of any new or worsening symptoms since  
224 SARS-CoV-2 infection (Long COVID); presence of 5 or more symptoms (severe Long COVID);  
225 specific symptom groups according to organ system involvement or phenotypic cluster; and  
226 individual symptoms when at least 25 individuals experienced the symptom. For individual and

227 grouped symptom outcomes, we developed 3 potential comparisons between the symptomatic  
228 group and (1) all individuals who reported absence of the symptoms of interest, regardless of  
229 Long COVID status (2) only individuals who were consistently asymptomatic and (3) individuals  
230 with Long COVID but not the symptoms of interest. Severe Long COVID was compared only to  
231 those without any reported symptoms.

232

233 We defined 6 groups of symptoms (symptom phenotypes) based on either organ system cluster.  
234 These include cardiopulmonary (cough, shortness of breath, chest pain, palpitations, and fainting),  
235 CNS-specific (problems with vision, headache, difficulty with concentration or memory, dizziness,  
236 and difficulty with balance), any neurologic symptom (problems with vision, headache, difficulty  
237 with concentration or memory, dizziness, difficulty with balance, trouble with smell or taste,  
238 phantosmia, or paresthesia), gastrointestinal (diarrhea, constipation, nausea, vomiting, loss of  
239 appetite, and abdominal pain), musculoskeletal (back pain, muscle pain, pain in the arms, legs, or  
240 joints), and upper respiratory (runny nose and sore throat).

241

242 Quality-of-life was assessed using the EuroQol-5D (EQ-5D), Patient Health Questionnaire  
243 depression scale (PHQ-8), and Generalized Anxiety Disorder scale (GAD-7). Individuals with  
244 Long COVID and the lowest overall quality-of-life (QOL) score measured via the visual analogue  
245 scale of the EQ-5D were compared to individuals with the highest overall QOL scores among  
246 those with and without Long COVID. Individuals with responses categorized as “moderate  
247 depression” on the PHQ-8 (score higher than 10) and “moderate anxiety” on the GAD-7 (score  
248 higher than 9) were compared to all participants with scores indicating less severe classifications  
249 than “moderate depression” and “moderate anxiety” in the following groups: (1) all participants  
250 regardless of Long COVID status (2) all participant without Long COVID and (3) all participants  
251 with Long COVID.

252 In addition, we recently demonstrated associations between Long COVID and other chronic latent  
253 viral infections, including serologic evidence suggesting recent Epstein-Barr virus (EBV)  
254 reactivation (26). For this reason, we also used binary variables to create groups indicating the  
255 presence of this condition.

256

### 257 **Biospecimen collection**

258 At each visit, whole blood was collected in EDTA tubes. Plasma was isolated and stored in -80F  
259 until the time of analysis.

260

### 261 **Phage Immunoprecipitation and Sequencing (PhIP-Seq)**

262 PhIP-Seq was performed following our previously published vacuum-based PhIP-Seq protocol  
263 (23) (<https://www.protocols.io/view/scaled-high-throughput-vacuum-hip-protocol-ewov1459kvr2/v1>).

264

### 265 **PhIP-Seq analysis**

266 All analysis (except when specifically stated otherwise) was performed at the gene-level, in which  
267 all reads for all peptides mapping to the same gene were summed, and 0.5 reads were added to  
268 each gene to allow inclusion of genes with zero reads in mathematical analyses. Within each  
269 individual sample, reads were normalized by converting to the percentage of total reads. To  
270 normalize each sample against background non-specific binding, a fold-change(FC) over mock-IP  
271 was calculated by dividing the sample read percentage for each gene by the mean read-  
272 percentage of the same gene for the AG bead only controls. This FC signal was then used for  
273 side-by-side comparison between samples and cohorts. Samples which had a FC of 5 or greater  
274 were considered enriched for an antibody, and samples with a FC of 6 standard deviations above  
275 the mean of pre-COVID controls were considered positive for an autoantibody. FC values were  
276

277 also used to calculate z-scores for each disease category sample by using each respective control  
278 (as specified in figures and results), and for each control sample by using all remaining controls.  
279 These z-scores were used for the logistic-regression feature weighting. In the case peptide-level  
280 analysis, raw reads were normalized by calculating the number of reads per 100,000 reads.

281

## 282 **Statistical methods**

283 All statistical analysis was performed in Python using the Scipy Stats package. A two-way  
284 Kolmogorov-Smirnoff(KS) test was used for comparisons of FC PhIP-Seq data between groups of  
285 samples, except in the case of specifically looking for those genes with increased signal only in  
286 the disease-cohort in which a one-way KS test was employed. The logistic regression machine-  
287 learning classifiers were performed using our recently described methods (23). Utilizing the Scikit-  
288 learn package, logistic regression classifiers were applied to z-scored PhIP-Seq values from  
289 individuals with a designated disease category versus the designated control. A liblinear solver  
290 was used with L1 regularization, and the model was evaluated using a five-fold cross-validation (4  
291 of the 5 for training, 1 of the 5 for testing).

292

## 293 **Informed consent**

294 Participants provided written informed consent. The study was approved by the UCSF Institutional  
295 Review Board.

296

## 297 **FOOTNOTES**

### 298 **Acknowledgements**

299 We are grateful to the study participants and their medical providers. We acknowledge current and  
300 former LIINC clinical study team members Tamara Abualhsan, Andrea Alvarez, Khamal Anglin,  
301 Urania Argueta, Mireya Arreguin, Kofi Asare, Melissa Buitrago, Monika Deswal, Nicole DelCastillo,

302 Emily Fehrman, Halle Grebe, Heather Hartig, Yanel Hernandez, Rebecca Hoh, Beatrice Huang,  
303 Marian Kerbleski, Raushun Kirtikar, James Lombardo, Monica Lopez, Michael Luna, Sadie  
304 Munter, Lynn Ngo, Enrique Martinez Ortiz, Antonio Rodriguez, Justin Romero, Dylan Ryder, Ruth  
305 Diaz Sanchez, Matthew So, Celina Song, Viva Tai, Alex Tang, Cassandra Thanh, Fatima Ticas,  
306 Leonel Torres, Brandon Tran, Daisy Valdivieso, Deepshika Varma, and Meghann Williams; and  
307 LIINC laboratory team members Amanda Buck, Tyler-Marie Deveau, Joanna Donatelli, Jill Hakim,  
308 Nikita Iyer, Owen Janson, Brian LaFranchi, Christopher Nixon, Isaac Thomas, and Keirstinne  
309 Turcios. We thank Jessica Chen, Aidan Donovan, Carrie Forman, and Rania Ibrahim for  
310 assistance with data entry and review. We thank the UCSF AIDS Specimen Bank for processing  
311 specimens and maintaining the LIINC biospecimen repository. We are grateful to Elnaz Eilkhani  
312 and Monika Deswal for regulatory support.

313

#### 314 **Author Contributions**

315 AB, ST, BG, JDT, JNM, SGD, TJH, JLD, and MJP designed the study. JDT, JNM, SGD, TJH, and  
316 MJP designed and oversaw the LIINC cohort, with major contributions from BG, MSD, PYH, and  
317 JH. KA, BH, and RH managed cohort operations. Clinical data were collected by JR, BT, RK, HG,  
318 and MS. SL and SG managed the data and developed the clinical dataset. ST, SL, SG, and MJP  
319 selected participants for inclusion in this study. Biospecimens were processed in the laboratories  
320 of BG and TJH. CW, AS, and AM performed the measurements in the laboratories of MSA and  
321 JLD. AB performed the data analysis. AB, TJH, JLD, and MJP wrote the first draft of the paper,  
322 with input from all other authors. All authors edited the manuscript and approved the final version.

323

#### 324 **Funding**

325 This work was supported by NIH/NIAID 3R01AI141003-03S1 and NIH/NIAID R01AI158013 (to M  
326 Gandhi and M Spinelli), Pediatric Scientist Development Program and the Eunice Kennedy

327 Shriver National Institute of Child Health and Human Development (K12-HD000850 to A.  
328 Bodansky), and Chan Zuckerberg Biohub support for J. DeRisi.

329

330 **Conflicts of Interest**

331 TJH reports grants from Merck & Co, Gilead Sciences, and Bristol-Myers Squibb, and has  
332 provided consulting for Roche, outside the submitted work. SGD reports grants and/or personal  
333 fees from Gilead Sciences, Merck & Co., Viiv, AbbVie, Eli Lilly, ByroLogyx, and Enochian  
334 Biosciences, outside the submitted work. JD reports paid compensation for consulting for the  
335 Public Health Company and Allen & Co. MJP reports consulting fees from Gilead Sciences and  
336 AstraZeneca, outside the submitted work. All other authors report no potential conflicts.

337

338

339 **FIGURE LEGENDS**

340 **Figure 1: PhIP-Seq autoreactivities distinguish post-COVID sera from pre-COVID controls.**

341 Logistic regression comparing PhIP-Seq autoreactivities in all individuals with prior COVID  
342 infection compared to pre-COVID controls. Barplot showing autoreactivities with the top 20 logistic  
343 regression coefficients.

344

345 **Figure 2: Post-COVID anti-ARHGAP31 autoreactivities target specific region with similarity**  
346 **to SARS-CoV-2**

347 (A) Stripplots showing distribution of ARHGAP31 autoreactivities in Long COVID, individuals with  
348 prior COVID infection but without Long COVID, and pre-COVID controls. Dotted line at 6 standard  
349 deviations above mean of pre-COVID controls. (B) Distribution of anti-ARHGAP31 autoreactivity  
350 signal within ARHGAP31 full length protein. One specific fragment is targeted. (C) Amino-acid  
351 sequence of the autoreactive region of ARHGAP31 and amino-acid sequence of a region of  
352 SARS-CoV-2 Orf1a with similarity. Shown below is the multiple sequence  
353 alignment(ClustalOmega; asterisk=identical amino acid; colon=strongly similar properties with  
354 Gonnet PAM 250 matrix score >0.5; period=weakly similar with Gonnet PAM 250 matrix score  
355 between 0 and 0,5) and strong physical-chemical conservation (JalView; amino acid physical-  
356 chemical conservation scored on a scale of 1-11, Asterisk=score of 11 and identical amino acid,  
357 Plus=10, all properties conserved).

358

359 **Figure 3: Post-COVID autoreactivities are similarly distributed among Long COVID and**  
360 **controls.**

361 Hierarchically clustered (Pearson) heatmaps showing the PhIP-Seq enrichment for the top 20  
362 autoreactivities ranked by logistic regression coefficient in each Long COVID patient, each COVID  
363 convalescent patient, and each pre-COVID control.



364 **Figure 4: Few significantly increased autoreactivities in Long COVID symptom phenotypes.**

365 (A) Heatmap with p-values (Kolmogorov-Smirnov testing) of differences in autoantigen enrichment  
366 for all individuals with prior COVID infection with and without additional clinical factors. Top-row  
367 compares those with and without Long COVID. Lower rows show subcategories of Long COVID.  
368 (B) Stripplots showing the three autoantibodies with statistically significant enrichment in a post-  
369 COVID clinical phenotype. Dotted-lines show 6 standard-deviations above the mean of pre-  
370 COVID signal.

371

372 **Supplement 1: PhIP-Seq is unable to distinguish Long COVID symptom phenotypes from**  
373 **controls.**

374 (A) Logistic regression receiver operating characteristic (ROC) curves for Long COVID patients  
375 with different specified symptom phenotypes relative to patients previously infected with COVID  
376 without the phenotype, or (B) with and without EBV laboratory findings.

377

378

379 **REFERENCES**


- 380 1. Nalbandian A et al. Post-acute COVID-19 syndrome [Internet]. *Nat. Med.* [published online  
381 ahead of print: March 22, 2021]; doi:10.1038/s41591-021-01283-z
- 382 2. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and  
383 recommendations. *Nat. Rev. Microbiol.* 2023;1–14.
- 384 3. Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. *Trends*  
385 *Immunol.* 2022;43(4):268–270.
- 386 4. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An  
387 Overview of Biological Factors That May Contribute to Persistent Symptoms [Internet]. *Frontiers in*  
388 *Microbiology* 2021;12. doi:10.3389/fmicb.2021.698169
- 389 5. Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection:  
390 leveraging translational research methodology to address emerging questions. *Transl. Res.*  
391 2022;241:1–12.
- 392 6. Zuo Y et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19  
393 [Internet]. *Sci. Transl. Med.* 2020;12(570). doi:10.1126/scitranslmed.abd3876
- 394 7. Chang SE et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. *Nat.*  
395 *Commun.* 2021;12(1):5417.
- 396 8. Woodruff MC et al. Dysregulated naïve B cells and de novo autoreactivity in severe COVID-19  
397 [Internet]. *Nature* [published online ahead of print: August 31, 2022]; doi:10.1038/s41586-022-  
398 05273-0
- 399 9. Bastard P et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

- 400 [Internet]. *Science* 2020;370(6515). doi:10.1126/science.abd4585
- 401 10. Bastard P et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected  
402 individuals over 70 years old and account for ~20% of COVID-19 deaths [Internet]. *Sci Immunol*  
403 2021;6(62). doi:10.1126/sciimmunol.abl4340
- 404 11. Vazquez SE et al. Neutralizing Autoantibodies to Type I Interferons in COVID-19  
405 Convalescent Donor Plasma. *J. Clin. Immunol.* 2021;41(6):1169–1171.
- 406 12. van der Wijst MGP et al. Type I interferon autoantibodies are associated with systemic  
407 immune alterations in patients with COVID-19. *Sci. Transl. Med.* 2021;13(612):eabh2624.
- 408 13. Son K et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID  
409 symptoms [Internet]. *Eur. Respir. J.* [published online ahead of print: September 22, 2022];  
410 doi:10.1183/13993003.00970-2022
- 411 14. Seeßle J et al. Persistent symptoms in adult patients one year after COVID-19: a prospective  
412 cohort study [Internet]. *Clin. Infect. Dis.* [published online ahead of print: July 5, 2021];  
413 doi:10.1093/cid/ciab611
- 414 15. Su Y et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae [Internet]. *Cell*  
415 2022;0(0). doi:10.1016/j.cell.2022.01.014
- 416 16. Peluso MJ, Thomas IJ, Munter SE, Deeks SG, Henrich TJ. Lack of Antinuclear Antibodies in  
417 Convalescent Coronavirus Disease 2019 Patients With Persistent Symptoms. *Clin. Infect. Dis.*  
418 2022;74(11):2083–2084.
- 419 17. Schultheiß C et al. The IL-1 $\beta$ , IL-6, and TNF cytokine triad is associated with post-acute  
420 sequelae of COVID-19. *Cell Rep Med* 2022;3(6):100663.


- 421 18. Klein J et al. Distinguishing features of Long COVID identified through immune profiling  
422 [Internet]. *medRxiv* [published online ahead of print: August 10, 2022];  
423 doi:10.1101/2022.08.09.22278592
- 424 19. Bodansky A et al. NFKB2 haploinsufficiency identified via screening for IFN $\alpha$ 2 autoantibodies  
425 in children and adolescents hospitalized with SARS-CoV-2-related complications [Internet]. *J.*  
426 *Allergy Clin. Immunol.* [published online ahead of print: December 9, 2022];  
427 doi:10.1016/j.jaci.2022.11.020
- 428 20. Mandel-Brehm C et al. Kelch-like Protein 11 Antibodies in Seminoma-Associated  
429 Paraneoplastic Encephalitis. *N. Engl. J. Med.* 2019;381(1):47–54.
- 430 21. O'Donovan B et al. High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by  
431 programmable phage display. *Brain Commun* 2020;2(2):fcaa059.
- 432 22. Vazquez SE et al. Identification of novel, clinically correlated autoantigens in the monogenic  
433 autoimmune syndrome APS1 by proteome-wide PhIP-Seq [Internet]. *Elife* 2020;9.  
434 doi:10.7554/eLife.55053
- 435 23. Vazquez SE et al. Autoantibody discovery across monogenic, acquired, and COVID-19-  
436 associated autoimmunity with scalable PhIP-seq [Internet]. *Elife* 2022;11. doi:10.7554/eLife.78550
- 437 24. Larman HB et al. Autoantigen discovery with a synthetic human peptidome. *Nat. Biotechnol.*  
438 2011;29(6):535–541.
- 439 25. Peluso MJ et al. Persistence, magnitude, and patterns of postacute symptoms and quality of  
440 life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement.  
441 In: *Open forum infectious diseases*. Oxford University Press US; 2022:ofab640
- 442 26. Peluso MJ et al. Impact of pre-existing chronic viral infection and reactivation on the

443 development of long COVID [Internet]. *J. Clin. Invest.* [published online ahead of print: December  
444 1, 2022]; doi:10.1172/JCI163669


### Post-COVID vs Pre-COVID




### Top 20 Autoantigens



A




C



Long COVID n=121

Convalescent n=64

Pre-COVID n=67




<5 Fold Change>Mock-IP >20



A

>0.05 | **p-value** | 0.00

B

